Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLEGRO extension study of oral laquinimod in relapsing multiple sclerosis
NL-OMON43625Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of laquinimod in multiple sclerosis (MS), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Descriptive evaluation of long-term safety, tolerability, and effect on disease course. Started Dec 2009; status: active, not recruiting.
02
Drugs
laquinimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON43625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43625.